Design of a single-center, phase II trial to explore the efficacy and safety of ‘R-ISV-RO’ treatment in advanced tumors

This study is funded by the National Natural Science Foundation of China, No. 82272852; the Jiangsu Provincial Key Research and Development Program, BE2020619; the special fund project for clinical research of Nanjing Drum Tower Hospital, 2022-LCYJ-MS-09; and the fundings for Clinical Trials from the Affiliated Drum, 2022-LCYJ-PY-21. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Comments (0)

No login
gif